Gut Microbial Alteration in MPTP Mouse Model of Parkinson Disease is Administration Regimen Dependent

Abstract

Parkinson Disease (PD) is one of the most common neurodegenerative disorders characterized by loss of dopaminergic neurons involved in motor functions. Growing evidence indicates that gut microbiota communicates with the brain known as the gut-brain axis (GBA). Mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is commonly used in animal studies to investigate the GBA in PD. Various MPTP administration regimens are performed in PD mouse models involving one to multiple injections in 1 day or one injection per day for several days. The aim of this study is to investigate if the impact of MPTP on gut microbiota differs depending on the administration regimen. C57BL/6 mice were treated with acute or subchronic regimens of MPTP. Motor functions were assessed by open-field, catalepsy, and wire hanging tests. The cecum and the brain samples were obtained for microbiota and gene expression analyses, respectively. MPTP administration regimens differed in their ability to alter the gut microbiota. Firmicutes and Bacteroidota were both increased in subchronic mice while did not change and decreased, respectively, in acute mice. Verrucomicrobiota was elevated in acute MPTP mice but dropped in subchronic MPTP mice. Muribaculaceae was the predominant genus in all groups but acute mice. In acute mice, Akkermansia was increased and Colidextribacter was decreased; however, they showed an opposite trend in subchronic mice. These data suggest that MPTP mouse model cause a gut microbiota dysbiosis in an administration regimen dependent manner, and it is important to take consideration of mouse model to investigate the GBA in neurodegenerative diseases including PD. Graphical Abstract Supplementary Information The online version contains supplementary material available at 10.1007/s10571-023-01319-7.

Neuroprotective effects exerted by a combination of selected lactic acid bacteria in a mouse parkinsonism model under levodopa-benserazide treatment

“…Finally, taking into account that the composition of the intestinal microbiota affects the correct functioning of this barrier [25], and that it was also shown that alterations in the composition of the intestinal microbiota can accelerate the aggregation of α-synuclein, partly through the secretion of bacterial amyloid [26], the study of the microbiota, using faecal samples from the different groups, was carried out. In this sense, it is highlighted that although it was not possible to determine whether the changes in the intestinal microbiota were a cause or a consequence of the pathogenesis of the disease, it was established that a healthy microbiota can reduce the risk of developing PD [27]. The results obtained in our model showed that richness and abundance (alpha diversity), studied with different indices, was greater in the MPTP group than in the healthy control; while the different treatments showed intermediate values.…”

A probiotic formulation protects the dopaminergic neurons via attenuating the intestinal inflammation in mice of Parkinson’s disease

“…Probiotic is one of these promising therapies, which have been shown to prevent gut in ammation via regulating the bacterial composition, altering the various pro-in ammatory cytokines and enhancing the gut barrier [41]. The MPTP-induced changes or dysbiosis in gut microbiota have been well studied in the rodents [42,43] and probiotics have been found to improve the gut microbiota in both diversity and richness in MPTP-treated mice [44]. VSL#3®, a probiotic cocktail containing eight cultured bacteria, is usually prescribed for treatment of irritable bowel disease via restoring the gut microbial composition.…”